DLX-105
DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research[1].
Product Specifications
UNSPSC
12352203
Target
IFNAR; Interleukin Related; TNF Receptor
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[DLX-105]
References & Citations
[1]Tsianakas A, et al. The single-chain anti-TNF-α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis. Exp Dermatol. 2016 Jun;25 (6) :428-33.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1196233-01 0.5 mg (E-Coli)
Recombinant Dog Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Ask
View Details 
MBS1196233-02 0.05 mg (Baculovirus)
Recombinant Dog Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Ask
View Details 
MBS1196233-03 0.05 mg (Mammalian-Cell)
Recombinant Dog Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Ask
View Details MBS1196233-04 0.5 mg (Yeast)
Recombinant Dog Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Ask
View Details MBS1196233-05 1 mg (E-Coli)
Recombinant Dog Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Ask
View Details MBS1196233-06 0.1 mg (Baculovirus)
Recombinant Dog Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Ask
View Details